At a glance
ClinicalIndex Comparison Record- ✓San Francisco Jail inmate
- ✓Age 18 or older
- ✓Positive tuberculin skin test (TST ≥5 TU)
- ✓Meets current national criteria for therapy for tuberculosis infection
- ✕History of treatment-limiting reaction to isoniazid or rifamycins
- ✕Pregnancy or breast feeding
- ✕Active tuberculosis
- ✕AST or ALT >3 times upper limit of normal
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Trial of Short Course Rifampin Versus INH for LTBI in Jail
In Brief
A Phase 3 clinical trial evaluating Isoniazid and Rifampin for Tuberculosis. Completed, enrolled 364 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether an alternative drug, (rifampin) given daily, is better at treating tuberculosis (TB) and more tolerable than the usual drug treatment, isoniazid (INH). Study participants will include 972, TB infected, San Francisco Jail inmates, aged 18 or older. One group of volunteers will take INH two times a week for 9 months, and the other group will take rifampin daily for 4 months. Medication will be administered in jail and at the San Francisco TB Clinic if the volunteer is released from jail prior to completing the study. Participants will be seen daily for 4 months (rifampin group), and 2 times a week for 9 months (INH group) for directly observed therapy. Study procedures will include 5 symptom review visits and blood samples for lab testing. Follow-up will continue for each subject for five years after enrollment into the study.
Study Details
Timeline
Interventions
Isoniazid 900 mg twice weekly
Rifampin 600mg once per day